News & Press.
Learn the Latest Elutia Updates
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed...
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on...
Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference
SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a...
Elutia Announces Private Placement for Proceeds Up to $26 Million
– Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today...
Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
– Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products,...